Paper30003574
Concordance of PD-L1 expression in matched urothelial bladder cancer specimens.
de Jong JJ and 4 others. Histopathology, 2018. Cited by 28 papers, by iCite.
Cite this record
ConductScience Library. Concordance of PD-L1 expression in matched urothelial bladder cancer specimens. Papers, record 30003574. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30003574
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| B7-H1 Antigen | Major topic |
| Carcinoma, Transitional Cell | Major topic |
| Urinary Bladder Neoplasms | Major topic |
| Aged | |
| Cystectomy | |
| Female | |
| Humans | |
| Immunohistochemistry | |
| Lymphatic Metastasis | |
| Male | |
| Middle Aged | |
| Urinary Bladder |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| Roche | PubMed |
Source PubMed
Cited by17
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 28 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42755500 | Case Report: Radical nephroureterectomy after toripalimab plus disitamab vedotin in biomarker-non-enriched upper tract urothelial carcinoma. | Front Oncol | 2026 | https://conductscience.org/library/papers/42755500 | PubMed |
| 42729159 | Disease stage-dependent expression of ADC-related biomarkers in urothelial carcinoma. | Transl Androl Urol | 2026 | https://conductscience.org/library/papers/42729159 | PubMed |
| 39280671 | Are primary tumors suitable for biomarker-guided treatment of metastatic urothelial cancer? | Transl Androl Urol | 2024 | https://conductscience.org/library/papers/39280671 | PubMed |
| 39186130 | [German expert consensus on programmed cell death ligand 1 (PD-L1) testing in perioperative systemic therapy of muscle invasive bladder cancer]. | Urologie | 2024 | https://conductscience.org/library/papers/39186130 | PubMed |
| 39085255 | A tumor targeted nano micelle carrying astragaloside IV for combination treatment of bladder cancer. | Sci Rep | 2024 | https://conductscience.org/library/papers/39085255 | PubMed |
| 38844907 | Programmed death-ligand 1 expression in carcinoma of unknown primary. | BMC Cancer | 2024 | https://conductscience.org/library/papers/38844907 | PubMed |
| 38658905 | PD-L1 expression in tumor and inflammatory cells is associated with favorable tumor features and favorable prognosis in muscle-invasive urothelial carcinoma of the bladder not treated by immune checkpoint inhibitors. | BMC Urol | 2024 | https://conductscience.org/library/papers/38658905 | PubMed |
| 37877864 | The Many Faces of Urothelial Carcinomas: An Update From Pathology to Clinical Approach and Challenges in Practice. | Urol Res Pract | 2023 | https://conductscience.org/library/papers/37877864 | PubMed |
| 35616216 | PD-L1 expression and FGFR-mutations among Danish patients diagnosed with metastatic urothelial carcinoma: A retrospective and descriptive study. | APMIS | 2022 | https://conductscience.org/library/papers/35616216 | PubMed |
| 35267437 | Management of Patients with Metastatic Bladder Cancer in the Real-World Setting from the Multidisciplinary Team: Current Opinion of the SOGUG Multidisciplinary Working Group. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35267437 | PubMed |
| 33909149 | PD-L1 expression in urothelial bladder cancer varies more among specimen types than between companion assays. | Virchows Arch | 2021 | https://conductscience.org/library/papers/33909149 | PubMed |
| 33141317 | PD-L1 testing in urothelial bladder cancer: essentials of clinical practice. | World J Urol | 2021 | https://conductscience.org/library/papers/33141317 | PubMed |
| 32042618 | PD-L1 testing in urothelial carcinoma: are we there yet? | Transl Androl Urol | 2019 | https://conductscience.org/library/papers/32042618 | PubMed |
| 32034486 | PD-L1 expression in bladder primary in situ urothelial carcinoma: evaluation in BCG-unresponsive patients and BCG responders. | Virchows Arch | 2020 | https://conductscience.org/library/papers/32034486 | PubMed |
| 31930091 | PD-L1 assessment in urothelial carcinoma: a practical approach. | Ann Transl Med | 2019 | https://conductscience.org/library/papers/31930091 | PubMed |
| 31586196 | The Efficacy of Mitotane in Human Primary Adrenocortical Carcinoma Cultures. | J Clin Endocrinol Metab | 2020 | https://conductscience.org/library/papers/31586196 | PubMed |
| 31172245 | [Molecular tumor board-urothelial cancer]. | Urologe A | 2019 | https://conductscience.org/library/papers/31172245 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/30003574
GET https://conductscience.org/api/papers/v1/30003574/authors